GLENMARK PHARMACEUTICALS
Back to Balance Sheet
|
GLENMARK PHARMACEUTICALS Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹1,773 Cr | ₹109 Cr | ₹-357 Cr | ₹2,621 Cr | ₹1,270 Cr |
What is the latest Total Non-Current Liabilities ratio of GLENMARK PHARMACEUTICALS ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2026 | ₹1,773 Cr |
| Mar2025 | ₹109 Cr |
| Mar2024 | ₹-357 Cr |
| Mar2023 | ₹2,621 Cr |
| Mar2022 | ₹1,270 Cr |
How is Total Non-Current Liabilities of GLENMARK PHARMACEUTICALS Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹1,773 Cr | 1,521.43 | |
| Mar2025 | ₹109 Cr | Positive | |
| Mar2024 | ₹-357 Cr | Negative | |
| Mar2023 | ₹2,621 Cr | 106.48 | |
| Mar2022 | ₹1,270 Cr | - | |
Compare Total Non-Current Liabilities of peers of GLENMARK PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK PHARMACEUTICALS | ₹65,075.3 Cr | -0.9% | 4.6% | 13.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹456,090.0 Cr | 1% | -2.7% | 15.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹226,976.0 Cr | 0.7% | 17.1% | 40.1% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹185,639.0 Cr | -0.3% | -3.7% | 37.9% | Stock Analytics | |
| CIPLA | ₹115,216.0 Cr | -0.3% | 2.3% | -8.1% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹98,074.4 Cr | -1.4% | 0.7% | -6.2% | Stock Analytics | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | -0.9% |
4.6% |
13.8% |
| SENSEX | -0.6% |
1% |
-3.7% |
You may also like the below Video Courses